Global health targets face severe obstacles as millions live with chronic viral hepatitis while diagnosis and treatment rates remain exceptionally low.
Infection with the hepatitis B virus or hepatitis C virus stands as a primary global driver of cirrhosis and liver cancer. Data compiled for 2022 attribute roughly 1.3 million deaths to these two conditions, averaging about 3,500 fatalities every single day. Worldwide, the chronic reservoir spans 254 million people living with hepatitis B and 50 million dealing with chronic hepatitis C.
Controlling these pathogens requires distinct interventions. Available treatments suppress the virus without clearing it entirely. Conversely, no vaccine prevents hepatitis C, but direct-acting antivirals now offer a cure.
Global Care Cascade Deficits Threaten Elimination Targets
The primary barrier to managing hepatitis B lies within the care cascade. According to 2022 figures from the World Health Organization, a mere 13% of individuals with chronic hepatitis B—representing 34 million people—knew their infection status, and just 3% corresponding to 7 million patients had received treatment. Out of 194 member states, only eight countries were on track to meet the 60% diagnosis coverage target, while a mere four countries tracked toward the 50% treatment benchmark.
Progress on hepatitis C shows slightly higher awareness but stark delivery gaps. Across all chronic cases, 36% had received a diagnosis, and 20% had secured treatment. Global strategies aim for elimination as a public health threat
by 2030, yet modeling and policy evaluations indicate that current trajectories lag far behind what is required to curb rising mortality and transmission trends.
Occupational Screening Exposes Hidden Infection Risks in Medical Facilities
While global policymakers analyze macro-level data, hospital environments present localized occupational hazards. A cross-sectional observational study conducted across multidisciplinary facilities evaluated 1,643 healthcare workers and auxiliary staff to assess seroprevalence, predictors, and occult infections in regions with moderate-to-high endemicity. The investigation spanned from July 2023 to May 2025 across hospitals in the Republic of Dagestan.
Routine screening frameworks in multiple jurisdictions rely solely on hepatitis surface antigen detection, a method that frequently fails to catch occult infections. To uncover these hidden cases, researchers tested serum samples using enzyme-linked immunosorbent assays followed by real-time PCR testing for viral DNA and RNA among seropositive individuals. Final PCR testing for hepatitis B DNA among 129 screened personnel at a specific facility identified the genetic material in 4 workers who tested negative for the surface antigen but positive for core antibodies, establishing an occult infection prevalence of 3.1%.
Statistical Predictors of Past Viral Exposure Among Hospital Staff
Multivariable logistic regression analyses within the healthcare worker cohort demonstrated that antibody concentrations and demographic factors strongly predict past viral exposure. Individuals with antibody titers between 100 and 1,000 mIU/mL faced 4.65-fold higher odds of testing positive for core antibodies compared to staff with undetectable protective antibody levels. Age also emerged as a significant independent predictor, with the odds of exposure climbing by 4.7% for each advancing year of age.
Projected Regional Trajectories and Surveillance Needs
Official statistics trace a steady climb in chronic incidence rates.
Investigators emphasize that epidemiological surveillance must transition away from passive observation toward active monitoring of core and surface antibody statuses, paired with targeted PCR screening protocols and rigorous adherence to standard workplace precautions across all clinical settings.
